Novartis touts more late-stage data for inclisiran, the once-centerpiece heart drug spurned by the FDA

Novartis bet large on The Medicines Company’s RNAi heart drug inclisiran, expecting to shake up that segment of the market with a swift US approval. But after getting stiff-armed by the FDA last year, the pharma giant’s now releasing more post-hoc data in the hopes of finally running it past...

Click to view original post